This study is testing a new oral medication called LY4584180, sometimes given with Rituximab (an IV infusion), for adults with certain blood cancers like Lymphoma, Non-Hodgkin's, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. You may be able to join if you've already had at least two other treatments for your blood cancer or can't receive other available therapies. Researchers want to see how safe LY4584180 is, how well it works to shrink tumors, and how your body processes the medication. The study will track side effects and how many participants respond to the treatment. The status of this study is currently unclear.

Study design

This is an interventional study planning to enroll 460 participants. The phase of the study is not specified.

What's involved

The study could last about 9 months or possibly longer, including an initial screening period. Specific details about visits, procedures, or tests are not provided.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for serious side effects for up to 3 years. Tumor response will also be evaluated for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.